PELL Bio-Med Technology Co. Ltd. (6949.TW)

TWD 117.5

(0.43%)

Operating Income Summary of PELL Bio-Med Technology Co. Ltd.

  • PELL Bio-Med Technology Co. Ltd.'s latest annual operating income in 2023 was -411.24 Million TWD , down -74.18% from previous year.
  • PELL Bio-Med Technology Co. Ltd.'s latest quarterly operating income in 2024 Q1 was -88.86 Million TWD , up 9.85% from previous quarter.
  • PELL Bio-Med Technology Co. Ltd. reported an annual operating income of -236.1 Million TWD in 2022, down -20.49% from previous year.
  • PELL Bio-Med Technology Co. Ltd. reported an annual operating income of -195.96 Million TWD in 2021, down 0.0% from previous year.
  • PELL Bio-Med Technology Co. Ltd. reported a quarterly operating income of -88.86 Million TWD for 2024 Q1, up 9.85% from previous quarter.
  • PELL Bio-Med Technology Co. Ltd. reported a quarterly operating income of -120.67 Million TWD for 2023 Q3, up 4.71% from previous quarter.

Annual Operating Income Chart of PELL Bio-Med Technology Co. Ltd. (2023 - 2021)

Historical Annual Operating Income of PELL Bio-Med Technology Co. Ltd. (2023 - 2021)

Year Operating Income Operating Income Growth
2023 -411.24 Million TWD -74.18%
2022 -236.1 Million TWD -20.49%
2021 -195.96 Million TWD 0.0%

Peer Operating Income Comparison of PELL Bio-Med Technology Co. Ltd.

Name Operating Income Operating Income Difference
Apex Biotechnology Corp. 141.71 Million TWD 390.19%
Sinphar Pharmaceutical Co.,Ltd. 286.05 Million TWD 243.764%
Panion & Bf Biotech Inc. 156.82 Million TWD 362.226%
Chunghwa Chemical Synthesis & Biotech Co., Ltd. 280.8 Million TWD 246.45%
GenMont Biotech Incorporation 6.98 Million TWD 5985.031%
Abnova (Taiwan) Corporation 47.19 Million TWD 971.395%
Adimmune Corporation -722.74 Million TWD 43.1%
Tanvex BioPharma, Inc. -2.1 Billion TWD 80.424%
Polaris Group -1.84 Billion TWD 77.735%
Energenesis Biomedical CO.,LTD. -261.83 Million TWD -57.062%
UnicoCell Biomed Co., Ltd. -96.28 Million TWD -327.135%